Literature DB >> 7192182

The interaction of misonidazole with radiation, chemotherapeutic agents, or heat: a preliminary report.

I J Stratford, G E Adams, M R Horsman, S Kandaiya, S Rajaratnam, E Smith, C Williamson.   

Abstract

Survival of hypoxic cells exposed to misonidazole at 37 degrees C show an initial lag period after which survival decreases exponentially with time. Hypoxic cells incubated with misonidazole for a time equivalent to that of the lag period on the survival curve show increased sensitivity when subsequently given x-irradiation. This is consistent with previously published observations. In addition, preincubation of hypoxic cells with misonidazole ata 37 degrees C also renders cells more sensitive to subsequent treatments by heat or melphalan, mustine and cis-Pt(II). Preincubation must be in hypoxia for cells to become sensitive to a second insult; preincubation in air does not change cellular sensitivity even when this preexposure is 5 mM misonidazole for 3 days. The potential of exploiting a physiological property of most solid tumors, viz., hypoxia, in order to increase sensitivity of tumor cells to cytotoxic agents is discussed.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7192182

Source DB:  PubMed          Journal:  Cancer Clin Trials        ISSN: 0190-1206


  20 in total

1.  5-Fluorouracil-metronidazole combination therapy in metastatic colorectal cancer. Clinical, pharmacokinetic and in vitro cytotoxicity studies.

Authors:  Z Bardakji; J Jolivet; Y Langelier; J G Besner; J Ayoub
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

2.  Effect of hyperthermia on the activity of 1-[(4'-hydroxy-2'-butenoxy)methyl]-2-nitroimidazole, which is cytotoxic to hypoxic cells.

Authors:  T Kusumoto; Y Maehara; Y Emi; Y Sakaguchi; H Baba; M Sakaguchi; K Sugimachi
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

3.  In vitro potentiation of BCNU activity in rat brain tumour cells pretreated with misonidazole.

Authors:  D W Siemann; K Wolf; S Morrissey; K T Wheeler
Journal:  Br J Cancer       Date:  1984-06       Impact factor: 7.640

4.  Bleomycin and misonidazole cytotoxicity.

Authors:  M Korbelik; B Palcic; L D Skarsgard
Journal:  Br J Cancer       Date:  1985-04       Impact factor: 7.640

5.  Chemopotentiation in vivo: no loss of sensitization with fractionation.

Authors:  S A Hill; D W Siemann
Journal:  Br J Cancer       Date:  1984-10       Impact factor: 7.640

6.  Effect of misonidazole pretreatment on nitrogen mustard-induced DNA cross-linking in mouse tissues in vivo.

Authors:  D Murray; R E Meyn
Journal:  Br J Cancer       Date:  1984-12       Impact factor: 7.640

7.  Enhanced cell killing in lewis lung carcinoma and a human pancreatic-carcinoma xenograft by the combination of cytotoxic drugs and misonidazole.

Authors:  T C Stephens; V D Courtenay; J Mills; J H Peacock; C M Rose; D Spooner
Journal:  Br J Cancer       Date:  1981-04       Impact factor: 7.640

8.  Enhancement of the effect of cytotoxic drugs by radiosensitizers.

Authors:  W M Martin; N J McNally; J De Ronde
Journal:  Br J Cancer       Date:  1981-06       Impact factor: 7.640

9.  Modification of tumour and host response to cyclophosphamide by misonidazole and by WR 2721.

Authors:  P R Twentyman
Journal:  Br J Cancer       Date:  1981-06       Impact factor: 7.640

10.  Effect of clinical levels of misonidazole on the response of tumour and normal tissues in the mouse to alkylating agents.

Authors:  J M Brown; D G Hirst
Journal:  Br J Cancer       Date:  1982-05       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.